More than 90% of FDA inspections find pharmaceutical facilities operating at an acceptable level of CGMP compliance. However, the remaining cases show how failures in electronic records, audit trails, access controls, or system testing can quickly trigger serious regulatory concerns. Therefore, in 2026, CSV plays a critical role in pharma quality assurance by ensuring that GxP computerized systems work as intended, protect data integrity, and remain compliant throughout the validation lifecycle.
Table of Contents
What Is Computer System Validation (CSV)?
Computer System Validation (CSV) provides documented evidence that a computerized system consistently performs its intended GxP functions. It confirms that the system processes data correctly, protects electronic records, and supports reliable decision-making. Moreover, computer system validation in pharma helps companies control risks, define user requirements, test critical functions, and maintain compliance throughout the system lifecycle. Therefore, effective computer system validation strengthens data integrity and supports compliance with GAMP 5, 21 CFR Part 11, and EU GMP Annex 11.
Why Computerized System Validation Matters for GMP Compliance
Computerized system validation matters because pharmaceutical companies rely on digital systems to make critical GMP and batch-release decisions. However, weak validation can produce unreliable data, hide unauthorized changes, and weaken audit trail controls. Moreover, uncontrolled updates may cause the system to lose its validated state and create gaps in data integrity. Therefore, effective computer system validation in pharma helps companies protect electronic records, support defensible batch decisions, and maintain continuous GMP compliance.
Four CSV Controls Required Across the Validation Lifecycle
A GAMP 5–aligned validation approach requires more than one-time system testing. Instead, pharmaceutical companies must apply clear controls from initial planning through system retirement. Moreover, each control should address GxP risk, data reliability, traceability, and the continued validated state. The following four controls form the foundation of a compliant and inspection-ready validation lifecycle:
- Risk-Based GAMP 5 Planning and GxP System Classification (PDF)
- User Requirements, Risk-Based Testing, and Traceability (PDF)
- Data Integrity, Audit Trail Review, and Access Control (PDF)
- Change Control, Periodic Review, and System Retirement (PDF)
The following infographic shows how a risk-based lifecycle aligned with EU GMP Annex 11 controls GxP computerized systems from initial planning and testing through operation, review, and retirement.
Risk-Based GAMP 5 Planning and GxP System Classification (PDF)
GAMP 5 uses system risk, complexity, and GxP impact to define suitable validation activities. Therefore, teams should classify each system before they select testing depth, documentation, and control measures.
Download Good Practices for Computerised Systems in Regulated GxP Environments — PI 011-3 Here
User Requirements, Risk-Based Testing, and Traceability (PDF)
Clear user requirements help teams define what the system must do in daily GxP operations. Moreover, risk-based testing and traceability confirm that critical functions meet approved requirements.
Data Integrity, Audit Trail Review, and Access Control (PDF)
Access controls restrict system activities to authorized users, while audit trails record critical changes. In addition, regular audit trail reviews help teams identify unexplained actions and protect data integrity.
Download MHRA GxP Data Integrity Guidance and Definitions — Revision 1 Here
Change Control, Periodic Review, and System Retirement (PDF)
Change control evaluates how updates, patches, or configuration changes may affect validated functions. Meanwhile, periodic reviews and controlled retirement help maintain compliance throughout the system lifecycle.
Download EudraLex Volume 4, Annex 11: Computerised Systems Here
What Inspectors Expect From a Validated Computer System
During a GMP inspection, inspectors expect clear evidence that a computerized system performs its intended functions and protects reliable electronic records. Therefore, they review more than the final validation report; they also examine requirements, risk decisions, test results, user access, audit trails, changes, and periodic reviews.
The following table summarizes the key evidence that inspectors may request during a computerized system inspection:
| Inspection Area | Evidence Inspectors Expect | What Inspectors Verify |
|---|---|---|
|
User requirements and risk assessment |
Approved user requirements, intended-use documents, and risk assessments |
The company has defined critical GxP functions and data risks |
|
Validation testing |
Test protocols, results, screenshots, deviations, and approvals |
The system performs critical functions accurately and consistently |
|
Access control |
User lists, role definitions, administrator records, and access reviews |
Only authorized users can access, modify, or delete GxP data |
|
Audit trail review |
Audit trail settings, completed reviews, procedures, and investigations |
The company identifies and investigates critical or unexplained changes |
|
Change control and periodic review |
Impact assessments, change records, retesting evidence, and periodic review reports |
The system remains compliant and maintains its validated state |
Top Computer System Validation Failures Found During GMP Inspections
GMP inspectors often identify weak requirements, incomplete testing, excessive user access, missing audit trail reviews, and poorly controlled system changes. Moreover, companies may fail to investigate validation deviations or review systems throughout their lifecycle. Therefore, effective computer system validation in pharma must connect risk assessment, access control, testing, change control, and periodic review to protect data integrity and maintain the validated state.
The following infographic shows how weak GAMP 5 controls can escalate into data integrity risks, unsupported GMP decisions, and serious inspection findings.
Final Words
In 2024, the European Medicines Agency reported 210 GMP inspections, which shows that regulators continue to examine pharmaceutical quality systems closely. As companies rely more on digital platforms, inspectors also expect stronger evidence for data integrity, access control, audit trails, testing, and lifecycle oversight. Therefore, effective CSV should remain an ongoing quality process rather than a one-time documentation exercise. Companies that control computerized systems throughout their lifecycle can maintain the validated state and respond to GMP inspections with clear, reliable evidence.
Qualification and Validation for GMP Systems
Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.
FAQ
Inspectors expect approved user requirements, risk assessments, test evidence, traceability records, access reviews, audit trail reviews, change controls, and periodic review reports.
Companies should set the review frequency according to system risk, criticality, change history, incidents, and impact on product quality or electronic records.
Missing audit trail reviews can hide unauthorized changes, weaken data integrity, and undermine laboratory results, batch decisions, and GMP compliance.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.